Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
11 search results for:

Cemiplimab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 14-03-2023 | EMA | News | Article
    approvalsWatch

    EMA recommends extension to cemiplimab indication

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has endorsed the adoption of a new indication for cemiplimab, to treat patients with PD-L1-positive, advanced non-small-cell lung cancer (NSCLC) in combination with platinum-based chemotherapy.

    Author:
    Shreeya Nanda
  2. 10-11-2022 | FDA | News | Article
    approvalsWatch

    First-line cemiplimab–chemo approved for advanced NSCLC in USA

    medwireNews : Cemiplimab-rwlc plus chemotherapy can be used as a first-line treatment option for US patients with advanced non-small-cell lung cancer (NSCLC), following a positive decision by the FDA.

    Author:
    Shreeya Nanda
  3. 05-09-2022 | Lung cancer | News | Article

    First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression

    Adding cemiplimab to first-line platinum-doublet chemotherapy significantly improves outcomes for patients with advanced non-small-cell lung cancer, regardless of tumor PD-L1 expression or histology, EMPOWER-Lung 3 study data show.

    Author:
    Laura Cowen
    Published in:
    Nature Med 2022; doi:10.1038/s41591-022-01977-y
  4. 28-05-2021 | EMA | News | Article
    approvalsWatch

    EMA recommends cemiplimab for first-line NSCLC treatment

    medwireNews: The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the first-line use of cemiplimab in patients with non-small-cell lung cancer (NSCLC) and high PD-L1 expression.

    Author:
    Hannah Kitt
  5. 02-03-2021 | FDA | News | Article
    approvalsWatch

    FDA approves cemiplimab for high PD-L1-expressing NSCLC

    Cemiplimab may be given to patients without metastases who are unsuitable for resection or definitive chemoradiotherapy.

    Author:
    Lynda Williams
  6. 23-09-2020 | ESMO 2020 | Conference coverage | Article

    EMPOWER-Lung 1 shows cemiplimab efficacy for PD-L1-high advanced NSCLC

    Cemiplimab monotherapy offers a significant overall survival benefit compared with platinum-doublet chemotherapy for advanced non-small-cell lung cancer patients with a PD-L1 tumor cell expression of 50% or above, indicate initial EMPOWER-Lung 1 trial findings.

    Author:
    Lynda Williams
    Published in:
    ESMO Virtual Congress 2020: 19–21 September
  7. 04-06-2018 | Cutaneous squamous cell carcinoma | Article

    PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

    Migden MR et al.  N Engl J Med  2018. doi:10.1056/NEJMoa1805131

  8. 13-07-2022 | Immunotherapy | News | Article

    ICI therapy feasible in advanced cancer patients with kidney transplant using immunosuppression

    Overall, 13 patients were given nivolumab as per the trial protocol, two patients received the PD-1 inhibitor outside the trial, and two individuals received either avelumab or cemiplimab.

    Author:
    Lynda Williams
    Published in:
    Lancet Oncol 2022; doi: 10.1016/S1470-2045(22)00368-0 Lancet Oncol 2022; doi: 10.1016/S1470-2045(22)00395-3
  9. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    No survival benefit by adding chemotherapy to immunotherapy in PD-L1-high NSCLC

    Six trials included chemoimmunotherapy regimens that involved pembrolizumab, atezolizumab, or nivolumab plus ipilimumab, and six investigated immunotherapy only with pembrolizumab, atezolizumab, nivolumab, nivolumab plus ipilimumab, or cemiplimab.

    Author:
    Laura Cowen
    Published in:
    2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June
  10. 28-01-2022 | Basal cell carcinoma | Adis Journal Club | Article
    Advances in Therapy

    New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma

    Cutaneous squamous cell carcinoma is the second most frequent malignant skin cancer; when presenting in advanced or metastatic stage, alternative treatments are required; cemiplimab is a human monoclonal antibody directed against programmed cell death-1 receptor that acts by blocking T-cell inactivation and is the first drug approved for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma.

  11. 02-10-2018 | FDA | News | Article
    approvalsWatch

    First advanced cutaneous squamous cell carcinoma drug approved

    medwireNews : The US FDA has approved use of the PD-1 inhibitor cemiplimab-rwlc for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced disease who are unable to undergo surgery or radiotherapy with curative intent.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.